These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31632028)

  • 21. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
    Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
    Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S; Bolhassani A
    Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy.
    Chandra J; Teoh SM; Kuo P; Tolley L; Bashaw AA; Tuong ZK; Liu Y; Chen Z; Wells JW; Yu C; Frazer IH; Yu M
    J Immunol; 2021 Mar; 206(5):987-998. PubMed ID: 33504616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein vaccination with HPV16 E7/Pep-1 nanoparticles elicits a protective T-helper cell-mediated immune response.
    Mardani G; Bolhassani A; Agi E; Shahbazi S; Mehdi Sadat S
    IUBMB Life; 2016 Jun; 68(6):459-67. PubMed ID: 27094221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model.
    Liu TY; Giddam AK; Hussein WM; Jia Z; McMillan NA; Monteiro MJ; Toth I; Skwarczynski M
    Curr Drug Deliv; 2015; 12(1):3-8. PubMed ID: 25269453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
    Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor Immunity Induced by Genetic Immunization with Chitosan Nanoparticle Formulated Adjuvanted for HPV-16 E7 DNA Vaccine.
    Tahamtan A; Barati M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
    Iran J Immunol; 2018 Dec; 15(4):269-280. PubMed ID: 30593741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice.
    Ren F; Xu Y; Mao L; Ou R; Ding Z; Zhang X; Tang J; Li B; Jia Z; Tian Z; Ni B; Wu Y
    Cancer Biol Ther; 2010 Jan; 9(2):134-41. PubMed ID: 19901562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
    Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
    J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines.
    Lee SY; Oh JY; Kang TH; Shin HS; Cheng MA; Farmer E; Wu TC; Hung CF
    J Biomed Sci; 2019 May; 26(1):41. PubMed ID: 31133013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice.
    Mohseni AH; Razavilar V; Keyvani H; Razavi MR; Khavari-Nejad RA
    J Med Virol; 2019 Feb; 91(2):296-307. PubMed ID: 30192395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.
    Bungener L; de Mare A; de Vries-Idema J; Sehr P; van der Zee A; Wilschut J; Daemen T
    Antivir Ther; 2006; 11(6):717-27. PubMed ID: 17310816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model.
    Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
    Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.